1. Academic Validation
  2. Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370

Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370

  • Cephalalgia. 1999 Dec;19(10):851-8. doi: 10.1046/j.1468-2982.1999.1910851.x.
S Shepheard 1 L Edvinsson M Cumberbatch D Williamson G Mason J Webb S Boyce R Hill R Hargreaves
Affiliations

Affiliation

  • 1 Department of Pharmacology, Merck, Sharp and Dohme Neuroscience Research Laboratories, Harlow, Essex, UK. [email protected]
Abstract

This study investigated whether the selective 5HT1F receptor agonist LY334370 has other possible antimigraine mechanisms in addition to the proposed inhibition of dural plasma extravasation. LY334370 (up to 10(-5) M) had no vasoconstrictor effects on human cerebral arteries in vitro. It had no effect (up to 10 mg kg-1, i.v.) on neurogenic vasodilation of dural blood vessels produced by electrical stimulation of the dura mater in anesthetized rats. Nor had it any effect (at 3 mg kg-1, i.v.) on the hyperalgesia produced by injection of carrageenan into the paw of conscious rats or on nociceptive reflex responses in the spinalized, decerebrate rabbit (up to 3 mg kg-1, i.v.), indicating that it has no general analgesic properties. However, it significantly inhibited activation of second-order neurons in the trigeminal nucleus caudalis produced by electrical stimulation of the dura mater in anesthetised rats at 3 mg kg-1, i.v. These results provide evidence to suggest that LY334370 has a central mechanism of action in blocking the transmission of nociceptive impulses within the trigeminal nucleus caudalis and that this may represent a mechanism through which it has its antimigraine effect.

Figures
Products